Antipsychotic Maintenance Treatment: Time to Rethink?

1. Rossler W, Salize HJ, van Os J, Riecher-Rossler A. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 2005 Aug;15(4):399–409. 15925493

2. Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005 Sep;66(9):1122–9. 16187769

3. Wiersma D, Wanderling J, Dragomirecka E, Ganev K, Harrison G, an der HW, et al. Social disability in schizophrenia: its development and prediction over 15 years in incidence cohorts in six European centres. Psychol Med 2000 Sep;30(5):1155–67. 12027051

4. CRANE GE. Clinical psychopharmacology in its 20th year. Late, unanticipated effects of neuroleptics may limit their use in psychiatry. Science 1973 Jul 13;181(4095):124–8. 4711733

5. Royal College of Psychiatrists. Report of the Second Round of the National Audit of Schizophrenia (NAS) 2014. London: Healthcare Quality Improvement Partnership; 2014.

6. Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-up of an Early Dose Reduction/Discontinuation or Maintenance Treatment Strategy: Long-term Follow-up of a 2-Year Randomized Clinical Trial. JAMA Psychiatry 2013 Jul 3.

7. Harrow M, Jobe TH, Faull RN. Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study. Psychol Med 2012 Feb 17;1–11.

8. Baldessarini RJ, Viguera AC. Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 1995 Mar;52(3):189–92. 7872842

9. Leucht S, Heres S, Hamann J, Kane JM. Methodological issues in current antipsychotic drug trials. Schizophr Bull 2008 Mar;34(2):275–85. doi: 10.1093/schbul/sbm159 18234700

10. Whitaker R. Anatomy of an Epidemic. New York: Crown Publishers; 2010.

11. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012 Jun 2;379(9831):2063–71. doi: 10.1016/S0140-6736(12)60239-6 22560607

12. Belaise C, Gatti A, Chouinard VA, Chouinard G. Patient online report of selective serotonin reuptake inhibitor-induced persistent postwithdrawal anxiety and mood disorders. Psychother Psychosom 2012;81(6):386–8. doi: 10.1159/000341178 22964821

13. Cundall RL, Brooks PW, Murray LG. A controlled evaluation of lithium prophylaxis in affective disorders. Psychol Med 1972 Aug;2(3):308–11. 4562449

14. Suppes T, Baldessarini RJ, Faedda GL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991 Dec;48(12):1082–8. 1845226

15. Viguera AC, Baldessarini RJ, Hegarty JD, van Kammen DP, Tohen M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 1997 Jan;54(1):49–55. 9006400

16. Lu ML, Pan JJ, Teng HW, Su KP, Shen WW. Metoclopramide-induced supersensitivity psychosis. Ann Pharmacother 2002 Sep;36(9):1387–90. 12196057

17. Diamond BI, Borison RL. Basic and clinical studies of neuroleptic-induced supersensitivity psychosis and dyskinesia. Psychopharmacol Bull 1986;22(3):900–5. 2879312

18. Borison RL, Diamond BI, Sinha D, Gupta RP, Ajiboye PA. Clozapine withdrawal rebound psychosis. Psychopharmacol Bull 1988;24(2):260–3. 3212159

19. Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand 2006 Jul;114(1):3–13. 16774655

20. Lieberman JA, Koreen AR, Chakos M, Sheitman B, Woerner M, Alvir JM, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry 1996;57 Suppl 9:5–9. 8823344

21. Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry 1995 Mar;52(3):173–88. 7872841

22. Emsley R, Nuamah I, Hough D, Gopal S. Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophr Res 2012 Jun;138(1):29–34. doi: 10.1016/j.schres.2012.02.030 22446143

23. Moncrieff J. Questioning the 'neuroprotective' hypothesis: does drug treatment prevent brain damage in early psychosis or schizophrenia? Br J Psychiatry 2011 Feb;198(2):85–7. doi: 10.1192/bjp.bp.110.085795 21282776

24. Zipursky RB, Reilly TJ, Murray RM. The Myth of Schizophrenia as a Progressive Brain Disease. Schizophr Bull 2012 Dec 7.

25. McGlashan TH. Rationale and parameters for medication-free research in psychosis. Schizophr Bull 2006 Apr;32(2):300–2. 16461574

26. Waddington JL, Youssef HA, Kinsella A. Cognitive dysfunction in schizophrenia followed up over 5 years, and its longitudinal relationship to the emergence of tardive dyskinesia. Psychol Med 1990 Nov;20(4):835–42. 1980953

27. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008 Mar;21(2):151–6. doi: 10.1097/YCO.0b013e3282f53132 18332662

28. Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, Money R, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry 2010 Apr;71(4):463–74. doi: 10.4088/JCP.07m03890yel 20156410

29. Kim J, Macmaster E, Schwartz TL. Tardive dyskinesia in patients treated with atypical antipsychotics: case series and brief review of etiologic and treatment considerations. Drugs Context 2014;3:212259. doi: 10.7573/dic.212259 24744806

30. Ryu S, Yoo JH, Kim JH, Choi JS, Baek JH, Ha K, et al. Tardive dyskinesia and tardive dystonia with second-generation antipsychotics in non-elderly schizophrenic patients unexposed to first-generation antipsychotics: a cross-sectional and retrospective study. J Clin Psychopharmacol 2015 Feb;35(1):13–21. doi: 10.1097/JCP.0000000000000250 25485636

31. Dorph-Petersen KA, Pierri JN, Perel JM, Sun Z, Sampson AR, Lewis DA. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology 2005 Sep;30(9):1649–61. 15756305

32. Fusar-Poli P, Smieskova R, Kempton MJ, Ho BC, Andreasen NC, Borgwardt S. Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal mri studies. Neurosci Biobehav Rev 2013 Jun 13.

33. Moncrieff J, Leo J. A systematic review of the effects of antipsychotic drugs on brain volume. Psychol Med 2010 Jan 20;1–14.

34. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009 Jan 15;360(3):225–35. doi: 10.1056/NEJMoa0806994 19144938

35. Murray-Thomas T, Jones ME, Patel D, Brunner E, Shatapathy CC, Motsko S, et al. Risk of mortality (including sudden cardiac death) and major cardiovascular events in atypical and typical antipsychotic users: a study with the general practice research database. Cardiovasc Psychiatry Neurol 2013;2013:247486. doi: 10.1155/2013/247486 24455199

36. Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 2006 Feb;188:122–7. 16449697

37. Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009 Aug 22;374(9690):620–7. doi: 10.1016/S0140-6736(09)60742-X 19595447

38. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010 Nov;123(2–3):225–33. doi: 10.1016/j.schres.2010.07.012 20692814

39. Pringsheim T, Lam D, Ching H, Patten S. Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials. Drug Saf 2011 Aug 1;34(8):651–68. doi: 10.2165/11592020-000000000-00000 21751826

40. Albaugh VL, Singareddy R, Mauger D, Lynch CJ. A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers. PLoS One 2011;6(8):e22662. doi: 10.1371/journal.pone.0022662 21857944

41. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002 Jan 3;346(1):16–22. 11777998

42. Chan HY, Chen CH, Chen JJ, Sun HJ, Chiu HJ, Chang CJ. A comparison of risperidone and olanzapine for schizophrenia patients intolerance of neuroleptic-induced extra-pyramidal syndromes. Journal of the European College of Neuropsychopharmacology 2003;13:S316.

43. Moncrieff J, Cohen D, Mason JP. The subjective experience of taking antipsychotic medication: a content analysis of Internet data. Acta Psychiatr Scand 2009 Aug;120(2):102–11. doi: 10.1111/j.1600-0447.2009.01356.x 19222405

44. Barbui C, Nose M, Bindman J, Schene A, Becker T, Mazzi MA, et al. Sex differences in the subjective tolerability of antipsychotic drugs. J Clin Psychopharmacol 2005 Dec;25(6):521–6. 16282831

45. Harrow M, Jobe TH. Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: a 15-year multifollow-up study. J Nerv Ment Dis 2007 May;195(5):406–14. 17502806

46. Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry 2007 May;68(5):654–61. 17503973

47. Faber G, Smid HG, Van Gool AR, Wunderink L, Wiersma D, van den Bosch RJ. Neurocognition and recovery in first episode psychosis. Psychiatry Res 2011 Jun 30;188(1):1–6. doi: 10.1016/j.psychres.2010.11.010 21122926

48. Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009 Nov 14;374(9702):1677–86. doi: 10.1016/S0140-6736(09)61457-4 19878986

49. BARI investigators. The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol 2007 Apr 17;49(15):1600–6. 17433949

50. Gardos G, Cole JO. Maintenance antipsychotic therapy: is the cure worse than the disease? Am J Psychiatry 1976 Jan;133(1):32–6. 2021